-37% Average Reduction in Scar Tissue Observed-
Report is Available for Download at: www.lifesciadvisors.com/clients/rxi
During the recent 2013 BIO CEO Conference, which took place in New York City, RXi Pharmaceuticals presented new exciting preliminary blinded data for RXI-109 from their scar prevention and reduction studies. Noticeable reductions in scar tissue were observed in two studies and there appears to be a clear correlation between CTGF expression and scar area, providing strong evidence of the mechanism of action.
Incision Sites in Study 1201 Have Reductions in Scar Tissue. Figure 1 on the next page displays a staining of incision sites from one of three subjects in cohort 4 of study 1201 that received a single 7.5 mg injection of RXI-109. The red outline in the figures effectively shows the surface area of the scar and it is clear that half of the incision sites have noticeably less surface area than the other half, indicating a big difference in the two groups (treatment versus placebo) While the data is blinded, the difference between the two groups is striking and investors should take note.
Target Appears Validated – A Correlation Between a Reduction in CTGF Expression and a Reduction in Scar Surface Area was Observed. Figure 2 shows that in this patient, the smaller wound area depicted in 2A appears to correlate with lower CTGF expression levels. RXI-109 knocks down CTGF levels. Higher CTGF expression (represented in the figure by brown staining) correlates to greater surface area of the scar. We believe these results, while still blinded and preliminary, strongly suggest validation of CTGF as an appropriate target for the prevention of scars and we believe the differences observed between the two groups is likely due to RXI-109 action.